On June 10, 2026, the Alliance of U.S. Startups and Inventors for Jobs (USIJ) sent a letter to Senate HELP Committee Chairman Bill Cassidy opposing the Medication Affordability and Patent Integrity Act and the Ensuring Timely Access to Generics Act of 2025, urging their removal from the committee’s June 17 markup. USIJ maintains that the Medication Affordability and Patent Integrity Act would burden the USPTO and chill R&D investment through burdensome compliance requirements, while the Ensuring Timely Access to Generics Act rests on a legally flawed premise given that generics already account for more than 90 percent of U.S. prescriptions filled.
“Legislation that undermines patent quality, validity, or enforceability — even legislation framed as protecting patients — will reduce the capital flowing to drug development, slow the pipeline of new treatments, and ultimately harm the American patients it purports to help.”
USIJ Urges Senate HELP Committee to Remove Patent-Weakening Bills from June 17 Markup
On June 10, 2026, the Alliance of U.S. Startups and Inventors for Jobs (USIJ) sent a letter to Senate HELP Committee Chairman Bill Cassidy opposing the Medication Affordability and Patent Integrity Act and the Ensuring Timely Access to Generics Act of 2025, urging their removal from the committee’s June 17 markup. USIJ maintains that the Medication Affordability and Patent Integrity Act would burden the USPTO and chill R&D investment through burdensome compliance requirements, while the Ensuring Timely Access to Generics Act rests on a legally flawed premise given that generics already account for more than 90 percent of U.S. prescriptions filled.